Global Blood Therapeutics scores FDA nod for Oxbryta, forecasts ‘paradigm shift’ in sickle cell disease
Another day, another early FDA nod. Global Blood Therapeutics has its first drug approval, and it’s one that’ll bring a “paradigm shift” in how patients with sickle cell disease are treated, execs say. On Monday, the FDA approved Oxbryta, formerly...
Fujifilm to invest $120M in gene therapy, build center in Texas
The Japan-based company plans to spend $55 million on the center while also outfitting its joint venture with new clean rooms and bioreactors.